Cargando…
A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia
Arsenic trioxide (ATO) combined with all trans retinoic acid (ATRA) is the first choice for the treatment of low and medium risk acute promyelocytic leukemia (APL). Clinical studies reported that the combination of ATO and ATRA could achieve a significant curative effect. However, the retinoic acid...
Autores principales: | Liu, Xiao, Yin, Weiwei, Widjaya, Andy Samuel, Yang, Yueying, Liu, Yunhu, Jiang, Yanyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shenyang Pharmaceutical University
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609443/ https://www.ncbi.nlm.nih.gov/pubmed/34849168 http://dx.doi.org/10.1016/j.ajps.2021.07.003 |
Ejemplares similares
-
CD71-mediated liposomal arsenic-nickel complex combined with all-trans retinoic acid for the efficacy of acute promyelocytic leukemia
por: Liu, Xiao, et al.
Publicado: (2023) -
Retinoic Acid and Arsenic for Treating Acute Promyelocytic Leukemia
por: Zhou, Guang-Biao, et al.
Publicado: (2005) -
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia
por: Ma, Ya-Fang, et al.
Publicado: (2022) -
Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives
por: McCulloch, Derek, et al.
Publicado: (2017) -
Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress
por: Masciarelli, S, et al.
Publicado: (2018)